<?xml version="1.0" encoding="UTF-8"?>
<lom xmlns="http://ltsc.ieee.org/xsd/LOM" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://ltsc.ieee.org/xsd/LOM http://standards.ieee.org/reading/ieee/downloads/LOM/lomv1.0/xsd/lom.xsd">
<general>
<title>
<string language="el">Prothymosin a and a prothymosin α-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes</string>
</title>
<language>eng</language>
<identifier>
<catalog>URI</catalog>
<entry>http://hdl.handle.net/10795/3424</entry>
</identifier>
<subject>
<string language="el">εμβόλια</string>
<string language="el">καρκίνος</string>
<string language="el">θεραπευτική</string>
</subject>
<description>
<string language="el">Background:
Active cancer immunotherapies are beginning to yield clinical benefit, especially those using peptide-pulsed dendritic cells (DCs). Different adjuvants, including Toll-like receptor (TLR) agonists, commonly co-administered to cancer patients as part of a DC-based vaccine, are being widely tested in the clinical setting. However, endogenous DCs in tumor-bearing individuals are often dysfunctional, suggesting that ex vivo educated DCs might be superior inducers of anti-tumor immune responses. We have previously shown that prothymosin alpha (proTα) and its immunoreactive decapeptide proTα(100–109) induce the maturation of human DCs in vitro. The aim of this study was to investigate whether proTα- or proTα(100–109)-matured DCs are functionally competent and to provide preliminary evidence for the mode of action of these agents.
Results:
Monocyte-derived DCs matured in vitro with proTα or proTα(100–109) express co-stimulatory molecules and secrete pro-inflammatory cytokines. ProTα- and proTα(100–109)-matured DCs pulsed with HER-2/neu peptides induce TH1-type immune responses, prime autologous naïve CD8-positive (+) T cells to lyse targets expressing the HER-2/neu epitopes and to express a polyfunctional profile, and stimulate CD4+ T cell proliferation in an HER-2/neu peptide-dependent manner. DC maturation induced by proTα and proTα(100–109) is likely mediated via TLR-4, as
25 shown by assessing TLR-4 surface expression and the levels of the intracellular adaptor molecules TIRAP, MyD88 and TRIF.
Conclusions:
Our results suggest that proTα and proTα(100–109) induce both the maturation and the T cell stimulatory capacity of DCs. Although further studies are needed, evidence for a possible proTα and proTα(100–109) interaction with TLR-4 is provided. The initial hypothesis that proTα and the proTα-derived immunoactive decapeptide act as “alarmins”, provides a rationale for their eventual use as adjuvants in DC-based anti-cancer immunotherapy.</string>
</description>
<description>
<string language="el">15 pp.</string>
</description>
</general>
<lifecCycle>
<contribute>
<source>LOMv1.0</source>
<value>creator</value>
<entity><![CDATA[BEGIN:VCARD
FN: Ioannou, Kyriaki
N: Ioannou, Kyriaki
"VERSION:3.0"
END:VCARD]]></entity>
</contribute>
<contribute>
<source>LOMv1.0</source>
<value>Scientific Coordinator</value>
<entity><![CDATA[BEGIN:VCARD
FN: Τσιτσιλώνη, Ουρανία
N: Τσιτσιλώνη, Ουρανία
"VERSION:3.0"
END:VCARD]]></entity>
</contribute>
<contribute>
<source>LOMv1.0</source>
<value>Project Executing Organisation</value>
<entity><![CDATA[BEGIN:VCARD
FN: Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)
N: Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)
"VERSION:3.0"
END:VCARD]]></entity>
</contribute>
<date>
<dateStamp>2013-09-22</dateStamp>
</date>
</lifecCycle>
<educational>
<learningResourceType>
<source>Digital Library of the Operational Programme "Education and Lifelong Learning" abstract types</source>
<value>Text</value>
</learningResourceType>
</educational><classification><keyword>
<string language="el">Prothymosin alpha</string>
</keyword>
<keyword>
<string language="el">Immunoreactive peptide</string>
</keyword>
<keyword>
<string language="el">Dendritic cells</string>
</keyword>
<keyword>
<string language="el">TH1 immune responses</string>
</keyword>
<keyword>
<string language="el">TLR-4, Adjuvant</string>
</keyword>
<keyword>
<string language="el">HER-2/neu peptides</string>
</keyword>
</classification>
<technical>
<location>http://bmcimmunol.biomedcentral.com/articles/10.1186/1471-2172-14-43</location>
</technical>
<technical>
<size>2120532</size>
<format>application/pdf</format>
<location>http://repository.edulll.gr/edulll/bitstream/10795/3424/2/3424_1.33_%ce%94%ce%97%ce%9c_22_9_13.pdf</location>
</technical>
<annotation></annotation><metaMetadata><identifier>
<catalog>URI</catalog>
<entry>http://hdl.handle.net/10795/3424</entry>
</identifier>
<contribute>
<entity><![CDATA[BEGIN:VCARD
FN:National Documentation Centre - National Hellenic Research Foundation
N:National Documentation Centre - National Hellenic Research Foundation
"VERSION:3.0"
END:VCARD]]></entity>
<role><source>LOMv1.0</source><value>creator</value></role>
<date><dateTime>2016-05-25T12:48:37Z</dateTime></date>
</contribute>
<contribute>
<entity><![CDATA[BEGIN:VCARD
FN:National Documentation Centre - National Hellenic Research Foundation
N:National Documentation Centre - National Hellenic Research Foundation
"VERSION:3.0"
END:VCARD]]></entity>
<role><source>LOMv1.0</source><value>validator</value></role>
<date><dateTime>2016-05-25T12:48:37Z</dateTime></date>
</contribute>
<metadataSchema>LOMv1.0</metadataSchema>
<language>gre</language>
</metaMetadata>
<rights>
<cost>no</cost>
<copyright>no</copyright>
<description>Copyright EYD-EPEDBM (Operational Programme "Education and Lifelong Learning")</description>
</rights>
</lom>